[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported insider activity by President, Chief Executive Officer and Director Mark A. Goldsmith. On 11/25/2025, he exercised a stock option to buy 60,000 shares of common stock at an exercise price of $4.09 per share, then sold 60,000 shares of common stock in a transaction under code M/S.

He also reported open market sales of 3,000 shares of common stock at $75 per share from each of two trusts. A weighted average sale price of $75.0827 was reported for one of the sales executed in multiple trades. After these transactions, he directly beneficially owned 247,863 shares of common stock (including 193,475 restricted stock units), and held additional indirect positions of 67,424 shares in each of two revocable trusts and 570,050 shares in a separate revocable living trust. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		M(1)		60,000	A	$4.09	307,863(2)	D
Common Stock	11/25/2025		S(1)		60,000	D	$75.0827(3)	247,863(2)	D
Common Stock	11/25/2025		S		3,000	D	$75	67,424	I	Trust(4)
Common Stock	11/25/2025		S		3,000	D	$75	67,424	I	Trust(5)
Common Stock								570,050	I	Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.09	11/25/2025		M(1)			60,000	03/13/2023	03/12/2029	Common Stock	60,000	$0	77,708	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.

2. Includes 193,475 restricted stock units.

3. This transaction was executed in multiple trades at prices ranging from $75.00 to $75.3650. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. Held by Jonathan Goldsmith Revocable Trust.

5. Held by Rebecca Goldsmith Revocable Trust.

6. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RVMD President and CEO Mark A. Goldsmith report?

Mark A. Goldsmith reported exercising a stock option to acquire 60,000 shares of Revolution Medicines, Inc. common stock at an exercise price of $4.09 per share on 11/25/2025, followed by a sale of 60,000 shares of common stock reported under transaction codes M and S.

At what prices did the RVMD insider sell shares on November 25, 2025?

On 11/25/2025, Mark A. Goldsmith reported a sale of 60,000 shares of common stock at a weighted average price of $75.0827 per share, with trades executed between $75.00 and $75.3650. He also reported additional sales of 3,000 shares from each of two trusts at $75 per share.

How many RVMD shares does Mark A. Goldsmith beneficially own after these transactions?

After the reported transactions, Mark A. Goldsmith beneficially owned 247,863 shares of Revolution Medicines common stock directly, including 193,475 restricted stock units. Indirectly, he reported 67,424 shares held by the Jonathan Goldsmith Revocable Trust, 67,424 shares held by the Rebecca Goldsmith Revocable Trust, and 570,050 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

What stock options did the RVMD CEO exercise, and what remains outstanding?

He exercised a stock option (right to buy) for 60,000 shares of common stock at an exercise price of $4.09 per share. This option was originally exercisable from 03/13/2023 and is set to expire on 03/12/2029. Following the exercise, he reported owning 77,708 derivative securities (stock options) directly.

Was the RVMD insider trading under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What roles does Mark A. Goldsmith hold at Revolution Medicines (RVMD)?

Mark A. Goldsmith is identified as a Director and an Officer of Revolution Medicines, Inc., with his officer title listed in the remarks as President and Chief Executive Officer.